Cochrane
Library

Cochrane Database of Systematic Reviews

Anticholinergics for neuroleptic-induced acute akathisia (Review)

Rathbone J, Soares-Weiser K

Rathbone J, Soares-Weiser K.
Anticholinergics for neuroleptic-induced acute akathisia.
Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD003727.
DOI: [10.1002/14651858.CD003727.pub3](https://doi.org/10.1002/14651858.CD003727.pub3).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	3
OBJECTIVES	3
METHODS	3
RESULTS	6
DISCUSSION	6
AUTHORS' CONCLUSIONS	6
ACKNOWLEDGEMENTS	7
REFERENCES	8
CHARACTERISTICS OF STUDIES	9
ADDITIONAL TABLES	10
WHAT'S NEW	11
HISTORY	11
CONTRIBUTIONS OF AUTHORS	11
DECLARATIONS OF INTEREST	11
SOURCES OF SUPPORT	11
NOTES	12
INDEX TERMS	12

[Intervention Review]

Anticholinergics for neuroleptic-induced acute akathisia

John Rathbone¹, Karla Soares-Weiser²¹HEDS, SCHARR, The University of Sheffield, Sheffield, UK. ²Enhance Reviews Ltd, Wantage, UK**Contact address:** John Rathbone, HEDS, SCHARR, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK.
J.Rathbone@sheffield.ac.uk, John.Rathbone@nottingham.ac.uk.**Editorial group:** Cochrane Schizophrenia Group**Publication status and date:** Edited (no change to conclusions), published in Issue 2, 2012.**Citation:** Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD003727. DOI: [10.1002/14651858.CD003727.pub3](https://doi.org/10.1002/14651858.CD003727.pub3).

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Neuroleptic-induced akathisia is one of the most common and distressing early-onset adverse effects of first generation 'typical' antipsychotic drugs. It is associated with poor compliance with treatment, and thus, ultimately, with an increased risk of relapse. We assessed the role of anticholinergic drugs as an adjunct therapy to standard antipsychotic medication in the pharmacological treatment of this adverse effect.

Objectives

To review anticholinergic drugs for neuroleptic-induced acute akathisia.

Search methods

We searched the Cochrane Schizophrenia Group's Register (October 1999), Biological Abstracts (1982-1999), CINAHL (1982-1999), Cochrane Library (Issue 4 1999), EMBASE (1980-1999), LILACS (1982-1999), MEDLINE (1966-1999) and PsycLIT (1974-1999). References of all identified studies were inspected for more trials and we contacted first authors. Each included study was sought as a citation on the Science Citation Index database. For this 2005-6 update, we searched the Cochrane Schizophrenia Group's Register (July 2005).

Selection criteria

We included all randomised clinical trials of adjunctive anticholinergic drugs in addition to antipsychotic medication compared with placebo, for people with neuroleptic-induced acute akathisia.

Data collection and analysis

We quality assessed and extracted data independently. We calculated the fixed effects relative risk (RR), the 95% confidence intervals (CI) and, where appropriate, the number needed to treat (NNT) for homogeneous dichotomous data on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).

Main results

We identified no relevant randomised controlled trials.

Authors' conclusions

At present, there is no reliable evidence to support or refute the use of anticholinergics for people suffering from neuroleptic-induced acute akathisia. Akathisia is a distressing movement disorder that remains highly prevalent in people with schizophrenia, both in the developed and developing world. This review highlights the need for well designed, conducted and reported clinical trials to address the claims of open studies as regards the effects of the anticholinergic group of drugs for akathisia.

PLAIN LANGUAGE SUMMARY

Anticholinergics for neuroleptic-induced acute akathisia

Akathisia is a common and distressing adverse effect of antipsychotic drugs and is characterised by restlessness and mental unease, both of which can be intense. Akathisia is associated with patterns of restless movement, including rocking, walking on the spot when standing, shuffling and tramping, or swinging one leg on the other when sitting. People may constantly pace up and down in an attempt to relieve the sense of unrest. Several strategies have been used to decrease akathisia, and this review is one in a series addressing the effects of drug treatments on such symptoms. We found no trial-based evidence for the use of anticholinergic drugs for akathisia, thus rendering firm treatment recommendations impossible.

BACKGROUND

The management of schizophrenia and related disorders was revolutionised in the 1950s by the introduction of antipsychotic (or neuroleptic) medication. These medications are effective in the control of florid symptoms of psychoses such as hallucinations, thought disorder (impaired communication) and delusions. In addition to their therapeutic action in acute psychotic episodes, maintenance therapy with antipsychotic drugs is associated with a reduced risk of relapse (Schooler 1993). However, antipsychotic medication has been associated with a range of adverse effects for people taking these medications. These adverse effects can lead to poor compliance with neuroleptic treatment, and thus, ultimately, to an increased risk of relapse (Barnes 1993). Some of the most troublesome adverse effects associated with antipsychotic medication involve abnormal involuntary movements.

Shortly after the introduction of antipsychotic drugs, akathisia was recognised as one of the most common and distressing early-onset adverse effects. This movement disorder is characterised by a subjective report of inner restlessness, mental unease, or dysphoria, which can be intense (Marder 1991, Halstead 1994). Associated with this experience are patterns of restless movement, including rocking from foot to foot and walking on the spot when standing, and shuffling and tramping the legs, rocking back and forth, or swinging one leg on the other when sitting (Braude 1983). In severe cases, patients constantly pace up and down in an attempt to relieve the sense of unrest.

Estimates of the prevalence of akathisia in neuroleptic-treated people ranges between 20% and 75%, occurring more frequently in the first three months of treatment (Ayd 1961, Grebb 1995). It is usually related not only to acute administration of a neuroleptic, but also to a rapid dosage increase (Barnes 1992). Akathisia may be difficult to distinguish from psychotic agitation or anxiety, especially if the person describes a subjective experience of akathisia in terms of being controlled by an outside force (Grebb 1995). If the akathisia is mistaken for psychosis, the antipsychotic drug dose may be increased leading to a worsening of the condition.

Technical background

While the pathophysiology of neuroleptic-induced acute akathisia remains unknown, antagonism of mesocortical and mesolimbic dopaminergic pathways is a plausible if not completely satisfactory hypothesis. The notion that dopaminergic blockade underlies the emergence of akathisia is supported by the PET studies of Farde and co-investigators (Farde 1992). In one study these investigators examined striatal dopamine D2 receptor occupancy in patients who had responded to antipsychotic medication. In those who exhibited extrapyramidal side-effects (parkinsonism or akathisia) the D2 receptor occupancy ranged from 77-89%, while the range for those without such symptoms was 74-80%. These findings link D2 occupancy to extrapyramidal side effects.

The involvement of serotonergic mechanisms in the pathophysiology of akathisia is supported by the reported efficacy of ritanserin, a selective 5-HT₂ antagonist and the lower liability for akathisia with newer antipsychotic drugs with relatively potent 5-HT₂-receptor blockade. Further, the occasional occurrence of akathisia during treatment with SSRI antidepressants, which potentiate 5-HT neurotransmission, is now well recognised.

Drugs that influence relevant neurotransmitter functions, such as anticholinergics, beta-blockers, and benzodiazepines, have been proposed as treatments for neuroleptic-induced acute akathisia.

OBJECTIVES

To review the effects of anticholinergic drugs for the treatment of neuroleptic-induced acute akathisia compared with placebo.

A secondary objective is to examine a possible differential therapeutic effect of these interventions according to psychiatric diagnosis (schizophrenia and other related disorders, mood disorders and other disorders).

METHODS

Criteria for considering studies for this review

Types of studies

We sought all relevant randomised controlled trials. Where trials were described as 'double-blind', but only implied that they were randomised, such trials were to have been included in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were to have been added and included in the final analysis. If a substantive difference had been found we would have only used trials that were clearly randomised and the results of the sensitivity analysis would have been described. Quasi-randomised studies, such as those allocating by using alternate days of the week, would have been excluded.

Types of participants

We would have included people with neuroleptic-induced acute akathisia, diagnosed by any criteria, irrespective of gender, age or psychiatric diagnosis.

Types of interventions

1. Adjunctive anticholinergics: any dose or means of administration. We considered the following to be anticholinergic drugs: benhexol, benzotropine, biperiden, dexetimide, orphenadrine, procyclidine, scopolamine or trihexyphenidyl.

2. Placebo.

Anticholinergic drugs compared with other active drugs, such as benzodiazepines and centrally-acting beta-blockers, were not considered in this version of the review.

Types of outcome measures

1. Akathisia symptoms

1.1 Number of people failing to demonstrate a complete remission (that is, not showing a 100% reduction in symptoms)

1.2 Number of people failing to achieve at least 50% reduction in symptoms*

1.3 Number of people who dropped out due to lack of efficacy

1.4 Mean difference in severity of symptoms at endpoint

1.5 Mean changes in severity of akathisia symptoms between baseline and endpoint (see Methods section)

2. General mental state changes

2.1 Deterioration in general psychiatric symptoms (such as delusions and hallucinations)

2.2 Mean difference in severity of symptoms at endpoint
2.3 Mean changes in severity of symptoms between baseline and endpoint (see Methods section)

3. Acceptability and tolerability of treatment

3.1 Number of people who left the study early for any reason*

3.2 Number of people who left early because of adverse events

4. Adverse effects

4.1 Number of people who presented at least one adverse event*

4.2 Number of people whose adverse effects were 'severe'

4.3 Mean difference in severity of adverse effects at endpoint

4.4 Mean changes in severity of adverse effects between baseline and endpoint (see Methods section)

We pre-stated three cut-off points for reporting of outcomes: short term (less than six weeks), medium term (between six weeks and six months) and long term (over six months).

* We chose, number of people failing to achieve at least 50% reduction in symptoms; number of people who left the study early for any reason, and the number of people who presented at least one adverse event as the primary outcomes.

Search methods for identification of studies

1. Electronic searching for update July 2005

1.1 We searched the Cochrane Schizophrenia Group's register using the phrase:

[(akathisi* or acathisi* in REFERENCE Title, Abstract and Index Fields) or (akathisi* in STUDY Healthcare Condition)]

This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).

2. Details of previous electronic searches

2.1. We searched the Cochrane Schizophrenia Group's Register (May 1999) using the phrase:

[AKATHISI* or ACATHISI*]

2.2. We searched Biological Abstracts (January 1982 to March 1999) using the Cochrane Schizophrenia Group's search strategy for randomised controlled trials combined with the phrase:

[and AKATHISI* or ACATHISI*]

2.3. We searched the Cochrane Library (Issue 3, 1999) using the phrase:

[(akathisia-drug induced in ME) or AKATHISI* or ACATHISI*]

2.4. We searched EMBASE (January 1980 to March 1999) using the Cochrane Schizophrenia Group's search strategy for randomised controlled trials combined with the phrase:

[and (akathisia-drug induced in thesaurus -all subheadings) or AKATHISI* or ACATHISI*]

2.5. We searched LILACS (January 1982 to March 1999) using the Cochrane Schizophrenia Group's search strategy for randomised controlled trials combined with the phrase:

[and (akathisia-drug induced in thesaurus -all subheadings) or AKATHISI* or ACATHISI* or (Mh acatisia or Mh acatisia induzida por drogas)].

2.6. We searched MEDLINE (January 1966 to March 1999) using the Cochrane Schizophrenia Group's search strategy for randomised controlled trials combined with the phrase:

[and (akathisia-drug induced in thesaurus -all subheadings) or AKATHISI* or ACATHISI*]

2.7. We searched PsycLIT (January 1974 to March 1999) using the Cochrane Schizophrenia Group's search strategy for randomised controlled trials combined with the phrase:

[and (explode akathisia-drug induced in DE) or AKATHISI* or ACATHISI*]

2.8. SCISEARCH - Science Citation Index

We would have searched the SCISEARCH database for further reports of included studies. Reports of articles citing these studies would have been inspected in order to identify further trials. We would have hand searched the results for further trials and researched, within the bibliographic package, ProCite (version 4.0 for windows, DataPak software, 1998).

3. Reference searching

We inspected the references of all identified studies for further citations.

4. Personal contact

We would have contacted the first author of each included study for information regarding unpublished trials.

Data collection and analysis

1. Selection of trials

Initially (ARL) inspected each citation/abstract from the search results for relevance and we obtained copies of abstracts that reported the possibility of treatments being randomised. We (ARL, KSW), independently decided if the acquired studies met the inclusion criteria. We performed an inter-rater reliability study by means of the weighted Kappa coefficient as a measure of agreement for inclusion criteria. For the 2005 update we (KSW and JR) independently inspected and selected citations. If disagreement occurred and could not be resolved by discussion, we sought further information to resolve any dispute.

2. Assessment of methodological quality

We would have assessed the methodological quality of included trials in this review using the criteria described in the Cochrane Handbook (Higgins 2005) and the Jadad Scale (Jadad 1996). The former is based on the evidence of a strong relationship between allocation concealment and direction of effect (Schulz 1995). The categories are defined below:

A. Low risk of bias (adequate allocation concealment)

B. Moderate risk of bias (some doubt about the results)

C. High risk of bias (inadequate allocation concealment).

For the purpose of the analysis in this review, we included trials if they met the Cochrane Handbook criteria A or B.

The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale includes three items:

1. Was the study described as randomised?
2. Was the study described as double-blind?
3. Was there a description of withdrawals and drop outs?

Each item receives one point if the answer is positive. In addition, a point can be deducted if either the randomisation or the blinding/masking procedures described are inadequate. For this review we used a cut-off of two points on the Jadad scale to check the assessment made by the Handbook criteria. However we would not have used the Jadad Scale to exclude trials.

3. Data management

3.1 Data extraction

We (ARL, KSW) would have independently extracted data from included trials. Any disagreements were discussed, decisions documented and, where necessary, we contacted the authors of trials for clarification. If this had not been possible we would not have entered data and we would have added the trial to the list of those awaiting assessment. For the 2005 update we (KSW and JR) independently extracted data and any disagreements were again resolved through discussion, where this was not possible we contacted authors for further information.

3.2 Intention to treat analysis

We would have excluded data from studies where more than 50% of participants in any group were lost to follow up (this does not include the outcome of 'leaving the study early'). In studies with less than 50% dropout rate, we would have considered people leaving the study early to have had the negative outcome, except for the event of death.

4. Data analysis

4.1 Binary data

For binary outcomes (e.g. improved/not improved) we would have calculated the Relative Risk (RR) and its 95% confidence interval (CI). We also would have calculated the number needed to treat statistic (NNT) when results were statistically significant. Should heterogeneity have occurred (see section 5) we would have used a random effects model.

4.2 Continuous data

4.2.1 Normally distributed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, all data included in the review would have met the following criteria: i. standard deviations and means were reported in the paper or were obtainable from the authors; ii. when a scale started from 0 the standard deviation (SD), when multiplied by two was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution (Altman 1996)). iii. if a scale started from a positive value (such as PANSS that can have values from 30 to 210) the calculation described above in ii) was modified to take the scale starting point into account. In these cases skew would have been considered present if $2SD > (S - S_{min})$, where S is the mean score and S_{min} is the minimum score.

4.2.2 Endpoint versus change data: endpoint scale-derived data are finite, ranging from one score to another. Change data (endpoint minus baseline) are more problematic and in the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we would have presented change data in MetaView in order to summarise available information. In doing

this, we would have been assuming either that data were not skewed or that the analyses could cope with the unknown degree of skew. Where possible we would have presented endpoint data, and if both endpoint and change data had been available for the same outcomes, then we would have reported only the former.

4.2.3 Summary statistic: for continuous outcomes, we would have estimated a weighted mean difference (WMD) between groups. Again, if we had found heterogeneity (see section 5) we would have used a random effects model.

4.2.4 Valid scales

Unpublished scales are a source of bias in schizophrenia trials (Marshall 2000). Therefore, we would have only used continuous data from scales if the measuring instrument had been described in a peer-reviewed journal and the instrument was either a self report questionnaire or completed by an independent rater or relative (not the therapist).

4.2.5 Crossover studies

Only the first segment of crossover trials would have been used in order to exclude the potential additive effect in the subsequent segments of these trials (Armitage 1991).

4.2.6 Cluster trials: studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997; Gulliford 1999).

Had clustering not been accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions we would have sought to contact first authors of studies to obtain intra class correlation co-efficients of their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Should clustering have been incorporated into the analysis of primary studies, we would also have presented these data as if from a non-cluster randomised study, but would have adjusted for the clustering effect.

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation co-efficient (ICC) Design effect = $1 + (m-1) \times ICC$ (Donner 2002). If the ICC was not reported we would have assumed it to be 0.1 (Ukoumunne 1999).

5. Test for heterogeneity

Firstly, we would have considered all included studies within any comparison to judge clinical heterogeneity. Then we would have visually inspected graphs to investigate the possibility of statistical heterogeneity. This would have been supplemented, primarily, by employing the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate was equal to, or greater than 75%, this would have been interpreted as evidence of high levels of heterogeneity (Higgins 2003). In such cases, we would have sought to identify reasons for the presence of heterogeneity, and if found these outlying trial(s) were to have been removed

and analysed separately. Should reasons for heterogeneity not have been identified we would have analysed the results using a random effects model, which takes into account that the effects being estimated are not identical.

6. Publication bias

We would have entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias (Egger 1997).

7. Sensitivity analyses

We would have analysed the effect of including studies with high attrition rates in a sensitivity analysis, and where possible we would have investigated whether there were differences in outcome for people with either: (i) schizophrenia; (ii) mood disorders; or (iii) other psychiatric diagnoses.

8. General

Where possible, we would have entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for the experimental intervention.

RESULTS

Description of studies

1. Excluded studies

We excluded many studies upon first inspection of the electronic search results. We selected seven trials for further inspection but we excluded all of these after we had acquired and inspected the full papers. Three were not randomised (Adler 1987, Adler 1988, Hermesh 1988). As the focus of this review was primarily the absolute effect of anticholinergic medication, we excluded Gagrut 1978, Horiguchi 1992 and Neu 1972 because they did not involve a placebo group. It was unfortunate that Friss 1983 did not present data before the first crossover period. In this randomised crossover study, people with neuroleptic-induced akathisia were allocated valproate or biperiden or placebo. We contacted Dr Gerlach (author) who kindly replied but data had been destroyed and no further information was available. For the 2005-6 update we found four additional studies but had to exclude them all. Adler 1993 compared benztropine with placebo but data were not usable and nine of the participants were receiving benzodiazepines. Hirose 2000 used biperiden at different dosages but did not use a placebo control. Sachdev 1993 compared benztropine with placebo, but data were unusable and two of the six participants were also taking benzodiazepines. Zeng 1995 allocated people to dextimide and benhexolum but not placebo.

2. Awaiting assessment

No studies await assessment.

3. Ongoing studies

We know of no ongoing studies.

4. Included Studies

No studies met eligibility criteria for inclusion.

Risk of bias in included studies

No studies met eligibility criteria for inclusion.

Effects of interventions

1. The search

We retrieved one thousand and eight citations using the search strategy of 2002. Only seven citations related to anticholinergics for akathisia and all studies had to be excluded. For the update search of 2005 we found 342 citations. None were eligible for inclusion.

2. COMPARISON: ANY ANTICHOLINERGIC DRUG vs PLACEBO

We were unable to include any randomised trial for this review.

DISCUSSION

1. General

It is feasible that we were unable to include any studies because our entry criteria were too restrictive. Akathisia however remains common, despite the advent of the second-generation antipsychotics. Compelling neuro-physiological reasons exist for the potential value of the anticholinergic group of drugs for this distressing problem. We feel that management of people with akathisia should be based on high-grade evidence from well designed, conducted and reported randomised clinical trials. Studies such as Friss 1983 show that randomised trials are possible. The lack of trials in this area needs addressing.

AUTHORS' CONCLUSIONS

Implications for practice

1. For people with neuroleptic-induced acute akathisia

At present, there is no good evidence to support, or refute, the use of anticholinergic drugs for people suffering from neuroleptic-induced acute akathisia.

2. For clinicians

The question of whether anticholinergic drugs are really more effective than placebo remains to be proven. Should a person be experiencing distressing akathisia despite other treatment strategies, a trial of an anticholinergic drug could be warranted. However, close monitoring of progress and adverse effects would be indicated. It is understandable if clinicians, and people with neuroleptic-induced acute akathisia, felt that treatment outside of a randomised controlled trial designed to inform others, would be difficult to justify.

3. For managers or policy makers

There is a paucity of data regarding the clinical implications of using anticholinergic drugs in antipsychotic-induced acute akathisia, and a complete lack of data related to service utilisation, hospitalisation or functioning in the community.

Implications for research

1. General

As with all similar reviews, public registration of a study before anyone is randomised would ensure that participants could be confident that people would know that the study had at least taken place. Compliance with CONSORT (Moher 2001), both on the part of authors and editors, would help to clarify methodology and many outcomes. Failure to comply with CONSORT guidelines results in loss of data and confusion in results, neither of which helps clinicians, patients or managers.

2. Specific

Akathisia is a most distressing movement disorder that remains highly prevalent, both in the developed and developing world.

This review highlights the need for well designed, conducted and reported clinical trials ([Table 1](#)) to address the claims of open studies as regards the effects of the anticholinergic group of drugs for akathisia.

ACKNOWLEDGEMENTS

We would like to thank Adriano Resende Lima (ARL), Thomas BARNED and Josue Bacaltchuk for their contribution to an earlier

version of the review. We would also like to thank Kristian Wahlbeck, Leanne Roberts and Clive Adams for advice during the production of the protocol and Evandro da Silva Freire Coutinho for advice during the production of this review. We would also like to thank Clive Adams and Tessa Grant for their editorial support.

REFERENCES

References to studies excluded from this review

Adler 1987 {published data only}

Adler LA, Reiter S, Corwin J, Hemdal P, Angrist B, Rotrosen J. Differential effects of propranolol and benztropine in patients with neuroleptic-induced akathisia. *Psychopharmacology Bulletin* 1987;**23**(3):519-21.

Adler 1988 {published data only}

Adler LA, Reiter S, Corwin J, Hemdal P, Angrist B, Rotrosen J. Neuroleptic-induced akathisia: propranolol versus benztropine. *Biological Psychiatry* 1988;**23**:209-14.

Adler 1993 {published data only}

* Adler LA, Peselow E, Rosenthal M, Angrist B. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. *Psychopharmacology Bulletin* 1993;**29**(2):283-6.

Friss 1983 {published data only}

Friss T, Christensen R, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind, placebo, cross-over study with placebo. *Acta Psychiatrica Scandinavica* 1983;**67**:178-87.

Gagrat 1978 {published data only}

Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. *American Journal of Psychiatry* 1978;**135**(10):1232-3.

Hermesh 1988 {published data only}

Hermesh H, Molcho A, Munitz H. Successful propranolol therapy for neuroleptic-induced akathisia resistant to anticholinergic and benzodiazepine drugs. *Clinical Neuropharmacology* 1988;**11**(4):369-72.

Hirose 2000 {published data only}

Hirose S, Ashby CR. Intravenous biperiden in akathisia: an open pilot study. *International Journal of Psychiatry in Medicine* 2000;**30**(2):185-94.

Horiguchi 1992 {published data only}

Horiguchi J, Nishimatsu O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study. *Japanese Journal of Psychiatry and Neurology* 1992;**46**(3):733-9.

Neu 1972 {published data only}

Neu C, Demascio A, Dermigian E. Antiparkinsonian medication in the treatment of extrapyramidal side-effects: single or multiple daily doses?. *Current Therapeutic Research* 1972;**14**(5):246-51.

Sachdev 1993 {published data only}

* Sachdev P, Loneragan C. Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia. *Clinical Neuropharmacology* 1993;**16**(4):324-31.

Sachdev P, Loneragan C. Intravenous benztropine and propranolol challenges in tardive akathisia. *Psychopharmacology* 1993;**113**:119-22.

Zeng 1995 {published data only}

Zeng ZX, Jing LR, Liu L, Meng QL, Zhang YD. Dexetimide and benhexolium in the treatment of drug-induced akathisia: a double-blind controlled trial. *Chinese Journal of Pharmacoeconomics* 1995;**4**(2):72-3.

Additional references

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**:1200.

Armitage 1991

Armitage P. Should we cross-off the cross-over?. *British Journal of Clinical Pharmacology* 1991;**32**:1-2.

Ayd 1961

Ayd FJ. A survey of drug-induced extrapyramidal reactions. *JAMA* 1961;**175**:1054-60.

Barnes 1992

Barnes TRE. Neuromuscular effects of neuroleptics: akathisia. In: Lieberman J, Kane JM editor(s). *Adverse effects of psychotropic drugs*. New York: Guilford Publications, 1992:201-17.

Barnes 1993

Barnes TRE, Edwards JG. The side effects of antipsychotic drugs. I. CNS and neuromuscular effects. *Antipsychotic drugs and their side effects*. London: Harcourt Brace & Company, 1993.

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**:600.

Braude 1983

Braude WM, Barnes TRE, Gore S. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. *British Journal of Psychiatry* 1983;**143**:139-50.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**:2971-80.

Egger 1997

Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629-34.

Farde 1992

Farde L, Norstrom AL, Halldin C. PET studies of dopamine receptors in relation to antipsychotic drug treatment. *Clinical Journal of Neuropharmacology* 1992;**15** Suppl 1 Pt - A:468A-469A.

Grebb 1995

Grebb JA. Medication induced movement disorders. In: Kaplan HI, Sadock BJ editor(s). *Comprehensive textbook of psychiatry*. New York: Williams & Wilkins, 1995.

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**:876-83; 876-83.

Halstead 1994

Halstead SM, Barnes TR, Speller JC. Akathisia: prevalence and associated dysphoria in an inpatient population with chronic schizophrenia. *British Journal of Psychiatry* 1994;**164**(2):177-83.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2005

Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* 4.2.5 [updated May 2005]. In: Higgins JPT, Green S editor(s). *The Cochrane Library*. Chichester, UK: John Wiley & Sons, Ltd., 2005.

Jadad 1996

Jadad A, Moore A, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. *Controlled Clinical Trials* 1996;**17**:1-12.

Marder 1991

Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, et al. Plasma levels of fluphenazine in patients

receiving fluphenazine decanoate. *British Journal of Clinical Psychiatry* 1991;**158**:658-65.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249-52.

Moher 2001

Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA* 2001;**285**:1987-91.

Schooler 1993

Schooler NR, Keith SJ. The clinical research base for the treatment of schizophrenia. *Psychopharmacology Bulletin* 1993;**29**:431-46.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**:408-12.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):1-75.

References to other published versions of this review

Lima 2002

Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database Systematic Reviews* 2002, Issue 3.

Lima 2004

Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database Systematic Reviews* 2004, Issue 1.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Adler 1987	Allocation: not randomised.
Adler 1988	Allocation: not randomised.
Adler 1993	Allocation: randomised.

Anticholinergics for neuroleptic-induced acute akathisia (Review)

Study	Reason for exclusion
	Participants: people with chronic schizophrenia, schizoaffective disorder, major depression with psychosis. Interventions: propranolol versus benztropine versus placebo. Outcomes: no usable data, 9 of 28 participants were given concomitant benzodiazepines, no separate data available.
Friss 1983	Allocation: randomised, cross-over design. Participants: people whose diagnosis was not specified, suffering from neuroleptic-induced akathisia. Interventions: valproate versus biperiden versus placebo. Outcomes: no data about allocation in first period. Dr Gerlach (author) contacted and replied promptly; data were destroyed and no more information is available.
Gagrat 1978	Allocation: randomised. Participants: people with psychotic disorders, suffering from neuroleptic-induced akathisia. Interventions: benzodiazepine versus diphenhydramine, none versus placebo.
Hermesh 1988	Allocation: not randomised, not controlled clinical trial.
Hirose 2000	Allocation: unclear. Participants: people with psychotic disorders, suffering from neuroleptic-induced akathisia. Interventions: biperiden at different dosages.
Horiguchi 1992	Allocation: randomised. Participants: people with schizophrenia, suffering from neuroleptic-induced akathisia. Interventions: benzodiazepine versus anticholinergic, none versus placebo.
Neu 1972	Allocation: randomised. Participants: people with psychotic disorders, suffering from neuroleptic-induced akathisia. Interventions: anticholinergic versus anticholinergic, none versus placebo.
Sachdev 1993	Allocation: randomised. Participants: people with schizophrenia, suffering from neuroleptic-induced akathisia. Interventions: benztropine (iv) versus propranolol (iv) versus placebo (iv). Outcomes: no usable data, two of the 6 participants were taking benzodiazepines, no separate data available.
Zeng 1995	Allocation: unclear. Participants: people suffering from neuroleptic-induced akathisia. Interventions: dextimide versus benzhexolum, no placebo group.

ADDITIONAL TABLES

Table 1. Suggested design for future trials

Methods	Participants	Interventions	Outcomes	Notes
Allocation: randomised - clearly described. Blindness: double - described and tested. Duration: 6 months. Design: parallel. Setting: hospital/community. Consent: described.	Diagnosis: neuroleptic-induced akathisia - defined by clinically relevant criteria. N=300.* Age: any. Sex: any.	1. Anticholinergic used in everyday practice, for example benztropine + standard care. N=150. 2. Placebo + standard care. N=150.	Death. Clinically important improvement in akathisia.** Adverse effects. Acceptability of treatment. Leaving the study early.	* Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.

Table 1. Suggested design for future trials (Continued)

Loss: described.

Quality of life.
Economic data.

** Predefined binary outcome, even if scale-defined.

WHAT'S NEW

Date	Event	Description
18 January 2012	Amended	Contact details updated.

HISTORY

Protocol first published: Issue 1, 2000

Review first published: Issue 3, 2002

Date	Event	Description
13 April 2011	Amended	Contact details updated.
5 August 2009	Amended	Contact details updated.
23 April 2008	Amended	Converted to new review format.
23 August 2006	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

John Rathbone - selected studies, inputted data and report writing.

Karla Soares-Weiser - protocol production, searching and data extraction.

Josué Bacaltchuk - protocol production and report writing.

Thomas Barnes - protocol production and report writing.

DECLARATIONS OF INTEREST

None.

SOURCES OF SUPPORT

Internal sources

- Federal University of São Paulo, Brazil.
- Cochrane Schizophrenia Group, UK.
- FAPESP - State of São Paulo, Brazil.

External sources

- No sources of support supplied

NOTES

Cochrane Schizophrenia Group internal peer review complete (see Module).
External peer review scheduled.

INDEX TERMS

Medical Subject Headings (MeSH)

Akathisia, Drug-Induced [*drug therapy]; Antipsychotic Agents [*adverse effects]; Cholinergic Antagonists [*therapeutic use]

MeSH check words

Humans